Investigational drug · Phase 2
HW091077
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Refractory Chronic Cough.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "HW091077"
First trial start
2026
May 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HW091077", any sponsor or status.
Conditions studied
As listed on its trial records.
- Refractory Chronic Cough
Largest trials
Live from ClinicalTrials.gov: studies naming "HW091077" as an intervention, largest first.
- A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC).Pivotal-lookingNot yet recruiting
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.Industry
NCT07483489 · 180 participants (planned) · Start May 1, 2026 · Primary completion Aug 30, 2028
Drug: HW091077; HW091077 and 1 more · For: Refractory Chronic Cough
Newest research
PubMed records naming it or its code names, newest first.
- Development of a P2X3 receptor antagonist derived from eliapixant with improved properties for the treatment of chronic cough.
Zang Y, Li Q, Li Y, et al. · Eur J Med Chem 2025
Also in development for Refractory Chronic Cough
- CamlipixantBLU-5937Phase 34 trials
GSK · Refractory Chronic Cough, Cough, Irritable Bowel Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.